EDAP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Given the investor's beginner level, long-term strategy, and available capital, EDAP does not present a compelling buy opportunity at this time. While there are positive revenue growth trends in its HIFU business, the company's financial performance and technical indicators do not strongly support a buy decision. The absence of strong trading signals and mixed sentiment further supports a hold recommendation.
The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 42.4, suggesting no clear overbought or oversold condition. Moving averages are converging, showing no clear trend. Support and resistance levels indicate limited upside potential in the short term.
The HIFU business reported a 39% revenue growth in 2025, driven by strong U.S. demand. Record Q4 2025 HIFU revenue highlights growth in the medical device market.
Net income and EPS have significantly declined YoY. The stock has a 60% chance to drop slightly in the next day and a 7.22% chance of a decline in the next month.
In Q4 2025, revenue grew by 39% YoY, driven by HIFU sales. However, the company reported a net income loss of -$5.01 million, down -21.64% YoY, and EPS dropped by -23.53%. Gross margin improved to 43.02%, up 9.33% YoY.
No analyst rating or price target changes were provided in the data.
